GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Type
Public
HQ
Rockville, US
Founded
2003
Employees
38 (est)+12%
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

John J. Baldwin

John J. Baldwin

Director
Brian Hahn

Brian Hahn

Chief Financial Officer
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors
William Gust

William Gust

Director

GlycoMimetics Locations

Rockville, US

GlycoMimetics Metrics

GlycoMimetics Summary

Market capitalization

$139 M

Closing share price

$6.03
GlycoMimetics's latest market capitalization is $139 M.

GlycoMimetics Market Value History

26% of current employees of GlycoMimetics are female and 74% are male.

GlycoMimetics Company Life

You may also be interested in